About Vizgen
Vizgen focuses on spatial genomics, offering the MERSCOPE platform, which enables high-resolution imaging for analyzing biological samples at cellular and subcellular levels. This technology uses MERFISH chemistry to collect sensitive spatial data, particularly beneficial in immuno-oncology research for studying tumor and immune interactions. Vizgen differentiates itself by providing additional tools like a Gene Panel Design Portal and a cell segmentation tool, enhancing the research experience. The company's goal is to improve understanding of biological systems and advance cancer research.
Cambridge, MassachusettsHeadquarters
2019Year Founded
$132.5MTotal Funding
SERIES_CCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Ongoing patent litigation with 10x Genomics poses financial and operational risks.
Streamlining operations and reducing headcount may impact employee morale and productivity.
Dependency on partnerships for technological advancements could lead to risks if expectations aren't met.
Differentiation
Vizgen's MERFISH technology offers high accuracy and detection efficiency at subcellular resolution.
MERSCOPE platform integrates single-cell and spatial multiomics analyses for detailed tissue understanding.
Vizgen's Gene Panel Design Portal allows custom gene panels for MERSCOPE platform.
Upsides
Partnership with Scale Biosciences enhances data analysis capabilities with integrated technologies.
MERSCOPE Ultra Platform and MERFISH 2.0 increase market competitiveness with higher throughput.
Recent patent issuance strengthens Vizgen's intellectual property portfolio in spatial genomics.
Funding
Total raised$132.49 M
Latest valuation$426.00 M
StageSERIES_C
SERIES B
3/31/2021$37
$185.00 MSERIES A
12/31/2019$14
$70.00 M